Zonghua Li1, Michael G Heckman1, Takahisa Kanekiyo1, Yuka A Martens1, Gregory S Day1, Maria Vassilaki1, Chia-Chen Liu1, David A Bennett1, Ronald C Petersen1, Na Zhao1, Guojun Bu1. 1. From the Department of Neuroscience (Z.L., T.K., Y.A.M., C.-C.L., N.Z., G.B.), Division of Biomedical Statistics and Informatics, Department of Quantitative Health Sciences (M.G.H.), Division of Behavioral Neurology (G.S.D.), and Neuroscience Graduate Program (G.B.), Mayo Clinic, Jacksonville, FL; Division of Epidemiology, Department of Quantitative Health Sciences (M.V.), and Department of Neurology (R.C.P.), Mayo Clinic, Rochester, MN; and Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL.
Abstract
BACKGROUND AND OBJECTIVES: To identify clinicopathologic factors contributing to mild cognitive impairment (MCI) reversion to normal cognition. METHODS: We analyzed 3 longitudinal cohorts in this study: the Mayo Clinic Study of Aging (MCSA), the Religious Orders Study and Memory and Aging Project (ROSMAP), and the National Alzheimer's Coordinating Center (NACC). Demographic characteristics and clinical outcomes were compared between patients with MCI with or without an experience of reversion to normal cognition (referred to as reverters and nonreverters, respectively). We also compared longitudinal changes in cortical thickness, glucose metabolism, and amyloid and tau load in a subcohort of reverters and nonreverters in MCSA with MRI or PET imaging information from multiple visits. RESULTS: We identified 164 (56.4%) individuals in MCSA, 508 (66.8%) individuals in ROSMAP, and 280 (34.1%) individuals in NACC who experienced MCI reversion to normal cognition. Cox proportional hazards regression models showed that MCI reverters had an increased chance of being cognitively normal at the last visit in MCSA (HR 3.31, 95% CI 2.14-5.12), ROSMAP (HR 3.72, 95% CI 2.50-5.56), and NACC (HR 9.29, 95% CI 6.45-13.40) and a reduced risk of progression to dementia (HR 0.12, 95% CI 0.05-0.29 in MCSA; HR 0.41, 95% CI 0.32-0.53 in ROSMAP; and HR 0.29, 95% CI 0.21-0.40 in NACC). Compared with MCI nonreverters, reverters had better-preserved cortical thickness (β = 0.082, p <0.001) and glucose metabolism (β = 0.119, p = 0.001) and lower levels of amyloid, albeit statistically nonsignificant (β = -0.172, p = 0.090). However, no difference in tau load was found between reverters and nonreverters (β = 0.073, p = 0.24). DISCUSSION: MCI reversion to normal cognition is likely attributed to better-preserved cortical structure and glucose metabolism.
BACKGROUND AND OBJECTIVES: To identify clinicopathologic factors contributing to mild cognitive impairment (MCI) reversion to normal cognition. METHODS: We analyzed 3 longitudinal cohorts in this study: the Mayo Clinic Study of Aging (MCSA), the Religious Orders Study and Memory and Aging Project (ROSMAP), and the National Alzheimer's Coordinating Center (NACC). Demographic characteristics and clinical outcomes were compared between patients with MCI with or without an experience of reversion to normal cognition (referred to as reverters and nonreverters, respectively). We also compared longitudinal changes in cortical thickness, glucose metabolism, and amyloid and tau load in a subcohort of reverters and nonreverters in MCSA with MRI or PET imaging information from multiple visits. RESULTS: We identified 164 (56.4%) individuals in MCSA, 508 (66.8%) individuals in ROSMAP, and 280 (34.1%) individuals in NACC who experienced MCI reversion to normal cognition. Cox proportional hazards regression models showed that MCI reverters had an increased chance of being cognitively normal at the last visit in MCSA (HR 3.31, 95% CI 2.14-5.12), ROSMAP (HR 3.72, 95% CI 2.50-5.56), and NACC (HR 9.29, 95% CI 6.45-13.40) and a reduced risk of progression to dementia (HR 0.12, 95% CI 0.05-0.29 in MCSA; HR 0.41, 95% CI 0.32-0.53 in ROSMAP; and HR 0.29, 95% CI 0.21-0.40 in NACC). Compared with MCI nonreverters, reverters had better-preserved cortical thickness (β = 0.082, p <0.001) and glucose metabolism (β = 0.119, p = 0.001) and lower levels of amyloid, albeit statistically nonsignificant (β = -0.172, p = 0.090). However, no difference in tau load was found between reverters and nonreverters (β = 0.073, p = 0.24). DISCUSSION: MCI reversion to normal cognition is likely attributed to better-preserved cortical structure and glucose metabolism.
Authors: Mary Ganguli; Beth E Snitz; Judith A Saxton; Chung-Chou H Chang; Ching-Wen Lee; Joni Vander Bilt; Tiffany F Hughes; David A Loewenstein; Frederick W Unverzagt; Ronald C Petersen Journal: Arch Neurol Date: 2011-06
Authors: Liesbeth Aerts; Megan Heffernan; Nicole A Kochan; John D Crawford; Brian Draper; Julian N Trollor; Perminder S Sachdev; Henry Brodaty Journal: Neurology Date: 2017-05-10 Impact factor: 9.910
Authors: Rosebud O Roberts; David S Knopman; Michelle M Mielke; Ruth H Cha; V Shane Pankratz; Teresa J H Christianson; Yonas E Geda; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Walter A Rocca; Ronald C Petersen Journal: Neurology Date: 2013-12-18 Impact factor: 9.910
Authors: Isabelle Bos; Stephanie Vos; Frans Verhey; Philip Scheltens; Charlotte Teunissen; Sebastiaan Engelborghs; Kristel Sleegers; Giovanni Frisoni; Olivier Blin; Jill C Richardson; Régis Bordet; Magda Tsolaki; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Alberto Lleó; Peter Johannsen; Yvonne Freund-Levi; Lutz Frölich; Rik Vandenberghe; Sarah Westwood; Valerija Dobricic; Frederik Barkhof; Cristina Legido-Quigley; Lars Bertram; Simon Lovestone; Johannes Streffer; Ulf Andreasson; Kaj Blennow; Henrik Zetterberg; Pieter Jelle Visser Journal: Alzheimers Dement Date: 2019-03-08 Impact factor: 21.566
Authors: Duane L Beekly; Erin M Ramos; William W Lee; Woodrow D Deitrich; Mary E Jacka; Joylee Wu; Janene L Hubbard; Thomas D Koepsell; John C Morris; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2007 Jul-Sep Impact factor: 2.703
Authors: Kelsey R Thomas; Emily C Edmonds; Joel S Eppig; Christina G Wong; Alexandra J Weigand; Katherine J Bangen; Amy J Jak; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Steven D Edland; Mark W Bondi Journal: Alzheimers Dement Date: 2019-09-05 Impact factor: 21.566
Authors: Logan Dumitrescu; Emily R Mahoney; Shubhabrata Mukherjee; Michael L Lee; William S Bush; Corinne D Engelman; Qiongshi Lu; David W Fardo; Emily H Trittschuh; Jesse Mez; Catherine Kaczorowski; Hector Hernandez Saucedo; Keith F Widaman; Rachel Buckley; Michael Properzi; Elizabeth Mormino; Hyun-Sik Yang; Tessa Harrison; Trey Hedden; Kwangsik Nho; Shea J Andrews; Doug Tommet; Niran Hadad; R Elizabeth Sanders; Douglas M Ruderfer; Katherine A Gifford; Annah M Moore; Francis Cambronero; Xiaoyuan Zhong; Neha S Raghavan; Badri Vardarajan; Margaret A Pericak-Vance; Lindsay A Farrer; Li-San Wang; Carlos Cruchaga; Gerard Schellenberg; Nancy J Cox; Jonathan L Haines; C Dirk Keene; Andrew J Saykin; Eric B Larson; Reisa A Sperling; Richard Mayeux; David A Bennett; Julie A Schneider; Paul K Crane; Angela L Jefferson; Timothy J Hohman Journal: Brain Date: 2020-08-01 Impact factor: 13.501